Repository logo
 
Publication

Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer

2018Journal article Open access
Simple item page
dc.contributor.authorVendrell, Ines
dc.contributor.authorFerreira, Arlindo
dc.contributor.authorAbrunhosa-Branquinho, André
dc.contributor.authorSemedo, Patrícia Miguel
dc.contributor.authorPulido, Catarina F.
dc.contributor.authorJorge, Marília
dc.contributor.authorPina, Maria Filomena
dc.contributor.authorPinto, Conceição
dc.contributor.authorCosta, Luis
dc.date.accessioned2021-11-30T14:36:17Z
dc.date.available2021-11-30T14:36:17Z
dc.date.issued2018
dc.descriptionCopyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0pt_PT
dc.description.abstractCervical cancer (CC) is one of the acquired immunodeficiency syndrome (AIDS) defining diseases and the human immunodeficiency virus (HIV) infection is thought to relate with increased acute toxicity of chemoradiotherapy (CRT). We investigated the effect of HIV status in the incidence of neutropenia associated with cisplatin-based CRT for CC and its impact in treatment completion. This is a single-center retrospective cohort study. Data collection was performed for all the consecutive stage Ib-IV CC women treated with cisplatin-based CRT from 2012 to 2016, and with known HIV status. Sixty-one patients were included, 6 were HIV+. HIV+ patients had a higher risk of neutropenia at any cycle during cisplatin CRT [adjusted odds ratio (OR) 7.3, 95% confidence interval (95% CI) 1.02–52.3; P = .05]. Despite the absolute differences, mean neutrophil count was nonsignificantly lower in HIV+ women, both at baseline [4455/μL (interquartile range, IQR: 1830–6689) vs 6340 (IQR: 1720–18,970) for HIV−, P = .98] and at the end of treatment [1752/μL (IQR: 1100–2930) vs 3147/μL (IQR: 920–18,390) in HIV−; P = .06]. Moreover, when considering the effect of time, CRT seems to induce a consistent drop of neutrophils in both groups (P = .229). No febrile neutropenia events occurred. In HIV+ women, there were more CT cycle delays (P = .013), patients were more prone to use granulocyte colony-stimulating factor (G-CSF; HIV+ 40.0% vs HIV− 4.0%; P = .04) and less likely to complete at least 5 cycles of cisplatin (P = .02). All patients received adequate dose of pelvic RT, regardless of HIV status. HIV+ patients have a significantly increased risk of neutropenia during CRT treatment for CC and are less likely to complete chemotherapy with cisplatin.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMedicine (Baltimore). 2018 Jul;97(30):e11592.pt_PT
dc.identifier.doi10.1097/MD.0000000000011592pt_PT
dc.identifier.eissn1536-5964
dc.identifier.issn0025-7974
dc.identifier.urihttp://hdl.handle.net/10451/50222
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWolters Kluwer Health, Inc.pt_PT
dc.relation.publisherversionhttps://journals.lww.com/md-journal/pages/default.aspxpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectAIDSpt_PT
dc.subjectCervical cancerpt_PT
dc.subjectChemoradiotherapypt_PT
dc.subjectHIVpt_PT
dc.subjectNeutropenia riskpt_PT
dc.subjectOncologypt_PT
dc.titleChemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue30pt_PT
oaire.citation.startPagee11592pt_PT
oaire.citation.titleMedicinept_PT
oaire.citation.volume97pt_PT
person.familyNameVendrell
person.familyNameFerreira
person.familyNameAbrunhosa-Branquinho
person.familyNamePina
person.familyNameCosta
person.givenNameInes
person.givenNameArlindo
person.givenNameAndré
person.givenNameMaria Filomena Brazão Carvalho De
person.givenNameLuis
person.identifier.ciencia-idF112-254C-6DC4
person.identifier.ciencia-idB311-FEB7-B1D3
person.identifier.ciencia-id041E-4ADE-FB64
person.identifier.orcid0000-0002-1667-5526
person.identifier.orcid0000-0002-1567-9322
person.identifier.orcid0000-0001-8432-0324
person.identifier.orcid0000-0002-4782-7318
person.identifier.scopus-author-id56707990400
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication89bb974f-99df-482b-bddb-d8bf4c87bea7
relation.isAuthorOfPublication9192e5a3-8f47-42b4-9192-abd1484d32f1
relation.isAuthorOfPublication512a88ea-ebfa-4691-a024-43716648abb8
relation.isAuthorOfPublication42e5fbec-4b39-4458-a6a2-175045fa7a55
relation.isAuthorOfPublication8a2ab4c6-ba86-4433-b4b7-6256d81890e5
relation.isAuthorOfPublication.latestForDiscovery8a2ab4c6-ba86-4433-b4b7-6256d81890e5

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Chemoradiotherapy_completion.pdf
Size:
290.06 KB
Format:
Adobe Portable Document Format
Download

Collections

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais